Shirley Ryan AbilityLab is looking for adults with sub-acute spinal cord injuries (SCI) to participate in a trial of experimental drug NVG-291. For 12 weeks, participants will receive daily subcutaneous injections of either NVG-291 or a placebo. “In lab studies, NVG-291 improved locomotion and bladder recovery,” an AbilityLab announcement said. “Final testing of central nervous…